Trial reportJournal of the National Cancer Institute2018
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).
Trial report in Journal of the National Cancer Institute, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review.Nutrients · 2025Pooled it
- Coasting related to taxane-induced peripheral neuropathy in patients with breast cancer: a systematic review.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review.Journal of cancer survivorship : research and practice · 2023Pooled it
- Treatment for chemotherapy-induced peripheral neuropathy: A systematic review of randomized control trials.Frontiers in pharmacology · 2022Pooled it
- A Systematic Review and Meta-Analysis of the Effectiveness of Neuroprotectants for Paclitaxel-Induced Peripheral Neuropathy.Frontiers in oncology · 2021Pooled it
- Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial.Breast cancer research : BCR · 2025Trial
- Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.Cancer chemotherapy and pharmacology · 2024Trial
- Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Trial
- Pre-treatment vitamin D insufficiency predicts severe paclitaxel-induced sensory neuropathy in breast cancer patients: a prospective cohort study.Scientific reports · 2026Article
- Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.Nature reviews. Cancer · 2025Review
- The Lives of Older People With Advanced Cancer Who Live Alone During Outpatient Cancer Chemotherapy: A Descriptive Qualitative Study.Nursing & health sciences · 2025Article
- Acetyl-L-carnitine ameliorates atherosclerosis in LDLRFrontiers in nutrition · 2024Article
- Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates.iScience · 2023Review
- Acetyl-L-carnitine for the prevention of taxane-induced neuropathy in patients with breast cancer: a systematic review and meta-analysis.Research in pharmaceutical sciences · 2023Review
- Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study.Breast (Edinburgh, Scotland) · 2023Article
- l-carnitine: Nutrition, pathology, and health benefits.Saudi journal of biological sciences · 2023Review
- Chemotherapy-Induced Peripheral Neuropathy.Handbook of experimental pharmacology · 2023Article
- Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.Breast cancer research and treatment · 2022Article
- Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.Journal of cancer survivorship : research and practice · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 10 institutions in 1 country.
Funding
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of taxanes. Acetyl-L-carnitine (ALC) was unexpectedly found to increase CIPN in a randomized trial. We investigated the long-term patterns of CIPN among patients in this trial. Methods: S0715 was a randomized, double-blind, multicenter trial comparing ALC (1000 mg three times a day) with placebo for 24 weeks in women undergoing adjuvant taxane-based chemotherapy for breast cancer. CIPN was measured by the 11-item neurotoxicity (NTX) component of the FACT-Taxane scale at weeks 12, 24, 36, 52, and 104. We examined NTX scores over two years using linear mixed models for longitudinal data. Individual time points were examined using linear regression. Regression analyses included stratification factors and the baseline score as covariates. All statistical tests were two-sided. Results: Four-hundred nine subjects were eligible for evaluation. Patients receiving ALC had a statistically significantly (P = .01) greater reduction in NTX scores (worse CIPN) of -1.39 points (95% confidence interval [CI] = -2.48 to -0.30) than the placebo group. These differences were particularly evident at weeks 24 (-1.68, 95% CI = -3.02 to -0.33), 36 (-1.37, 95% CI = -2.69 to -0.04), and 52 (-1.83, 95% CI = -3.35 to -0.32). At 104 weeks, 39.5% on the ALC arm and 34.4% on the placebo arm reported a five-point (10%) decrease from baseline. For both treatment groups, 104-week NTX scores were statistically significantly different compared with baseline (P < .001). Conclusions: For both groups, NTX scores were reduced from baseline and remained persistently low. Twenty-four weeks of ALC therapy resulted in statistically significantly worse CIPN over two years. Understanding the mechanism of this persistent effect may inform prevention and treatment strategies. Until then, the potential efficacy and harms of commonly used supplements should be rigorously studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.